Jul 6–12, 2026 · 3 new studies, 1 review · Orthopaedic Oncology archive · All weeks
The new Orthopaedic Oncology research The Reduction sent the week of Jul 6–12, 2026, with the week’s most recent reviews, each with a one-line summary.
Get papers like these by email, free: subscribe to The Reduction, focused on your interests, on the days you pick.
Postoperative vascular endothelial growth factor inhibitor reintiation after 40 days reduced wound complications in spinal metastasis surgery compared with earlier resumption.
Single-cell transcriptomics identifies ADAMTS12 and RNASE1 as key drivers of osteosarcoma metastatic progression through malignant and immune cell signaling networks.
Lower denosumab doses reduced skeletal-related events risk while decreasing osteonecrosis of the jaw risk in metastatic cancer patients, suggesting dose reduction may optimize the benefit-harm profile.
Benign Bone Tumors of the Hand: Beyond Enchondromas.
Beyond enchondromas, hand surgeons should recognize benign bone tumors including osteogenic lesions, giant cell tumor, fibrous dysplasia, and unique entities like Nora lesions requiring distinct management approaches.
← Week of Jun 29 – Jul 5, 2026Week of Jul 13–19, 2026 →
Home · All weeks · Archive · Subscribe · FAQ
© 2026 The Reduction